Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989620 · ClinicalTrials.gov registry record
Long-Term Development of Muscular Dystrophy Outcome Assessments
A clinical trial of LGMD2A and LGMD2C, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05989620: Recruiting study of LGMD2A and LGMD2C, sponsored by Virginia Commonwealth University.
NCT05989620 is a study of LGMD2A and LGMD2C that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05989620, a study of LGMD2A and LGMD2C, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
Primary Outcome
The NSAD is a functional scale specifically designed to measure motor performance in individuals with LGMD. It consists of 29 items that are considered clinically relevant items from the adapted North Star Ambulatory Assessment and the Motor Function Measure 20 with a maximum score of 54.
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2029-05-01 |
What NCT05989620 shows while recruiting
NCT05989620 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 10 conditions, with LGMD2A appearing as the primary indexed condition, and to 0 interventions.
NCT05989620 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05989620 about?
NCT05989620 is a clinical study titled "Long-Term Development of Muscular Dystrophy Outcome Assessments". This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
What is the current status of trial NCT05989620?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-10-18. Estimated completion is 2029-05-01.
What conditions does trial NCT05989620 study?
This clinical trial studies the following conditions: LGMD2A, LGMD2C, LGMD1B, LGMD1C, LGMD1D.
Who is sponsoring clinical trial NCT05989620?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05989620 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for LGMD2A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI